mdl 100240 has been researched along with ramipril in 4 studies
| Studies (mdl 100240) | Trials (mdl 100240) | Recent Studies (post-2010) (mdl 100240) | Studies (ramipril) | Trials (ramipril) | Recent Studies (post-2010) (ramipril) |
|---|---|---|---|---|---|
| 21 | 9 | 0 | 2,151 | 606 | 509 |
| Protein | Taxonomy | mdl 100240 (IC50) | ramipril (IC50) |
|---|---|---|---|
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.004 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agabiti-Rosei, E; Bova, S; Neri, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP; Sacchetto, A | 1 |
| Agabiti-Rosei, E; Bova, S; Cavallin, M; Mazzocchi, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP | 1 |
| Agabiti-Rosei, E; Bianchi, R; De Ciuceis, C; Nussdorfer, GG; Paiardi, S; Porteri, E; Rezzani, R; Rizzoni, D; Rodella, L; Rossi, GP; Sleiman, I; Sticchi, D | 1 |
| Belloni, AS; Guidolin, D; Nussdorfer, GG; Pessina, AC; Rossi, GP; Seccia, TM; Sticchi, D | 1 |
4 other study(ies) available for mdl 100240 and ramipril
| Article | Year |
|---|---|
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Aorta; Benzazepines; Blood Pressure; Body Weight; Cardiovascular Diseases; Hypertension; In Vitro Techniques; Male; Neprilysin; Organ Size; Pyridines; Ramipril; Rats; Vasoconstriction | 2002 |
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.
Topics: Adrenomedullin; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzazepines; Biomarkers; Blood Pressure; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Heart; Hypertension; Male; Models, Cardiovascular; Neprilysin; Organ Size; Peptides; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B2; Receptors, Bradykinin; Severity of Illness Index; Systole; Treatment Outcome; Vasoconstrictor Agents | 2002 |
Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Benzazepines; Bradykinin; Bradykinin Receptor Antagonists; Disease Models, Animal; Drug Interactions; Hypertension; Immunohistochemistry; Male; Matrix Metalloproteinases; Mesenteric Arteries; Myography; Neprilysin; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Vascular Resistance; Vasoconstriction | 2004 |
The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Atrial Natriuretic Factor; Benzazepines; Creatinine; Fibrosis; Hypertension; Kidney; Male; Neprilysin; Pyridines; Ramipril; Rats; Receptor, Bradykinin B2 | 2006 |